Piera Angelillo

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Sara Mastaglio, Annalisa Ruggeri, Antonio M. Risitano et al. · Clinical Immunology · 2020 · 296 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro et al. · The Lancet Rheumatology · 2020 · 209 citations · Full text

Pharmacy, Immunology, Infectious Diseases +15

Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy

Evgeny Fominskiy, Anna Mara Scandroglio, Giacomo Monti et al. · Blood Purification · 2020 · 97 citations · Full text

Medicine, Internal Medicine, Nephrology +13

<i>MYD88</i> L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

Andrés J.M. Ferreri, Teresa Calimeri, Paolo Lopedote et al. · British Journal of Haematology · 2021 · 93 citations · Full text

Life Sciences, Immunology, Oncology +17

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Chiara Rusconi, Chan Y. Cheah, Toby A. Eyre et al. · Blood · 2022 · 46 citations · Full text

Medicine, Oncology, Pharmacotherapy +12